Review article · 2020 · Open access
Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
Journal of Hematology & Oncology, 13(1), 50 · Published 13 May 2020 · DOI 10.1186/s13045-020-00885-3
In brief
“Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy” is a 2020 review article by Xin Li and Yongcheng Song, published in Journal of Hematology & Oncology. OpenAlex counts 596 citations as of 19 November 2026, which puts it in the top 2% of works published in 2020 by citations. It is open access under a CC BY licence: the full text is free to read at Journal of Hematology & Oncology.
- Citations
- 596
- Most cited in
- 2025 (154)
- Field-weighted impact
- 4.51
- References
- 106
- Authors
- 2
Abstract
Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. A bifunctional PROTAC molecule consists of a ligand (mostly small-molecule inhibitor) of the protein of interest (POI) and a covalently linked ligand of an E3 ubiquitin ligase (E3). Upon binding to the POI, the PROTAC can recruit E3 for POI ubiquitination, which is subjected to proteasome-mediated degradation. PROTAC complements nucleic acid-based gene knockdown/out technologies for targeted protein reduction and could mimic pharmacological protein inhibition. To date, PROTACs targeting ~ 50 proteins, many of which are clinically validated drug targets, have been successfully developed with several in clinical trials for cancer therapy. This article reviews PROTAC-mediated degradation of critical oncoproteins in cancer, particularly those in hematological malignancies. Chemical structures, cellular and in vivo activities, pharmacokinetics, and pharmacodynamics of these PROTACs are summarized. In addition, potential advantages, challenges, and perspectives of PROTAC technology in cancer therapy are discussed.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Li, X., & Song, Y. (2020). Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy. Journal of Hematology & Oncology, 13(1), 50. https://doi.org/10.1186/s13045-020-00885-3
MLA 9
Li, Xin, and Yongcheng Song. “Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.” Journal of Hematology & Oncology, vol. 13, no. 1, 2020, p. 50. https://doi.org/10.1186/s13045-020-00885-3.
Chicago
Li, Xin and Yongcheng Song. 2020. “Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.” Journal of Hematology & Oncology 13 (1): 50. https://doi.org/10.1186/s13045-020-00885-3.
Harvard
Li, X. and Song, Y. (2020) ‘Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy’, Journal of Hematology & Oncology, 13(1), p. 50. doi:10.1186/s13045-020-00885-3.
IEEE
X. Li and Y. Song, “Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy,” Journal of Hematology & Oncology, vol. 13, no. 1, p. 50, 2020, doi: 10.1186/s13045-020-00885-3.
BibTeX
@article{li2020proteolysis,
title = {{Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy}},
author = {Li, Xin and Song, Yongcheng},
journal = {Journal of Hematology \& Oncology},
year = {2020},
volume = {13},
number = {1},
pages = {50},
doi = {10.1186/s13045-020-00885-3},
url = {https://doi.org/10.1186/s13045-020-00885-3}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2020 | 7 | |
| 2021 | 47 | |
| 2022 | 60 | |
| 2023 | 80 | |
| 2024 | 115 | |
| 2025 | 154 | |
| 2026 | 132 |
Its field-weighted citation impact is 4.51: it has been cited 4.51 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- PROTACs
- targeted protein degradation
- E3 ubiquitin ligase
- oncoprotein
- hematologic malignancies
- cancer therapy
- proteasomal degradation
- pharmacokinetics
Work with this paper
Most-cited papers in Biochemistry, Genetics and Molecular Biology
- PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENTOliver H. Lowry, NiraJ. Rosebrough, A. Lewis Farr and 1 more · Journal of Biological Chemistry · 1951 · 316,470 citations
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingM Bradford · Analytical Biochemistry · 1976 · 256,780 citations
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodKenneth J. Livak, Thomas D. Schmittgen · Methods · 2001 · 184,418 citations
- Molecular Cloning: A Laboratory ManualJoseph Sambrook, Elisabeth Fritsch, Tom Maniatis · UCLA - Biblioteca de Ciencias de la Salud · 1989 · 133,493 citations
- Basic Local Alignment Search ToolStephen F. Altschul, Warren R. Gish, Webb Miller and 2 more · Journal of Molecular Biology · 1990 · 100,529 citations
All highly cited Biochemistry, Genetics and Molecular Biology papers
Questions about this paper
How do I cite this paper in APA style?
Li, X., & Song, Y. (2020). Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy. Journal of Hematology & Oncology, 13(1), 50. https://doi.org/10.1186/s13045-020-00885-3
How many times has this paper been cited?
596 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Journal of Hematology & Oncology: sign in and open the PDF from this page.
Who wrote this paper?
Xin Li, Yongcheng Song.
What is the DOI of this paper?
10.1186/s13045-020-00885-3, permanently at https://doi.org/10.1186/s13045-020-00885-3. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.